Search results
Results From The WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
Anti-HER2 antibody. HER2-positive breast cancer, gastric cancer, pancreatic cancer (orphan) and gastro-oesophageal junction cancer. Cardiac dysfunction, infusion-related reactions, peripheral neuropathy and pulmonary toxicity (rare). 2.2 Tyrosine kinase inhibitor: Afatinib: PO: EGFR, HER2 and HER4 inhibitor. Non-small cell lung cancer.
T-cell transfer therapy: a treatment that takes T-cells from the tumor and selects or changes them in the lab to better attack cancer cells, then reintroduces them into the patient. Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system.
The James Cancer Hospital and Solove Research Institute. The Arthur G James Cancer Hospital and Richard J. Solove Research Institute is a dedicated cancer hospital and research center that is part of the university's Comprehensive Cancer Center, with a governance structure separate from, but coordinated with, Ohio State Wexner Medical Center.
Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. [4] [7] Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. [4] [7] Epcoritamab was co-developed by AbbVie and Genmab. [8]
Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly for patients with non-small cell lung cancer . [27] Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody in pivotal Phase 3 and Phase 2 clinical trials in solid tumors and hematologic cancers. [28]
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (commonly shortened to just The James) is part of The Ohio State University Wexner Medical Center and is one of the National Cancer Institute's Comprehensive Cancer Centers. [3] It is named after the founder Arthur G. James and is located in Columbus, Ohio, United States.